Revolution Medicines, INC. (RVMD) — SEC Filings
Latest SEC filings for Revolution Medicines, INC.. Recent 4 filing on Apr 17, 2026. AI-decoded analysis of earnings, risk factors, and insider trades.
View Revolution Medicines, INC. on SEC EDGAR
Overview
Revolution Medicines, INC. (RVMD) is a publicly traded company tracked on ReadTheFiling. The most recent enriched filing is a 4 filed on Apr 17, 2026: On April 17, 2026, Mark A. Goldsmith filed a Form 4 with the SEC, reporting changes in beneficial ownership of securities for Revolution Medicines, Inc. The filing details transactions that occurred on April 15, 2026. The company is involved in Biological Products.
Sentiment Summary
Across 3 filings, the sentiment breakdown is: 3 neutral. The dominant filing sentiment for Revolution Medicines, INC. is neutral.
Filing Type Overview
Revolution Medicines, INC. (RVMD) has filed 1 4, 1 FWP, 1 8-K with the SEC between Apr 2026.
Recent Filings (3)
-
Revolution Medicines: Insider Ownership Update
— 4 · Apr 17, 2026 Risk: low
On April 17, 2026, Mark A. Goldsmith filed a Form 4 with the SEC, reporting changes in beneficial ownership of securities for Revolution Medicines, Inc. The fil - FWP Filing — FWP · Apr 15, 2026
-
Revolution Medicines Files 8-K
— 8-K · Apr 13, 2026 Risk: low
Revolution Medicines, Inc. filed an 8-K on April 13, 2026, to report other events. The filing does not contain specific financial figures or new material agreem
Frequently Asked Questions
What are the latest SEC filings for Revolution Medicines, INC. (RVMD)?
Revolution Medicines, INC. has 3 recent SEC filings from Apr 2026, including 1 4, 1 FWP, 1 8-K. Each filing includes an AI-generated plain-English summary.
What is the overall sentiment of RVMD filings?
Across 3 filings, the sentiment breakdown is: 3 neutral. The dominant sentiment is neutral.
Where can I find Revolution Medicines, INC. SEC filings explained simply?
ReadTheFiling provides AI-powered plain-English summaries of all Revolution Medicines, INC. (RVMD) SEC filings, including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, and insider trades.